Introduction
Primary resistance
Secondary resistance
Immune phenotype
Next steps: combinatorial approaches to overcome resistance
Clinical data
Conclusion
Author | Indication | Regimen | Number of Patients | HR for death | HR for progression/death | ORR % |
---|---|---|---|---|---|---|
Wolchock et al. [17] | Untreated advanced melanoma | Nivo and Nivo/Ipi vs. Ipi alone | 945 | HR 0.55, 95% CI 0.45–0.69 for Nivo/Ipi vs. Ipi | HR 0.43, 95% CI 0.35–0.52 for Nivo/Ipi vs. Ipi | 57.6 for Ipi/Nivo |
Motzer et al. [18] | Untreated advanced renal cell cancer | Nivo/Ipi vs. Sunitinib | 1096 | HR 0.63, 99.8% CI 0.44–0.82 | HR 0.82, 99.1% CI 0.64–1.05; not significant | 42 for Ipi/Nivo |
Motzer et al. [19] | Untreated advanced renal cell cancer | Axitinib/Ave vs. Sunitinib | 886 | Final data not available yet | HR 0.61, 95% CI 0.475–0.790 | 62 for Axitinib/Ave |
Antonia et al. [22] | Stage III NSCLC | Chemorad/Durva vs. Chemorad | 709 | HR 0.86, 95% CI 0.54–0.86 | HR 0.52, 95% CI 0.42–0.65 | 28.4 for Chemorad/Durva |
Socinski et al. [24] | Stage metastatic non-squamous NSCLC | Chemo/Atezo/Bev (and Chemo/Atezo) vs. Chemo alone | 1202 | HR 0.78, 95% CI 0.64–0.96 For EGFR/ALK: HR 0.54, 95% CI 0.29–1.03 (not significant) | HR 0.62, 95% CI 0.52–0.74 | 63.5 for Chemo/Atezo/Bev |